The department promotes research on neurological diseases to increase knowledge of disease mechanisms, identify new therapeutic targets, develop procedures for early diagnosis and screening of subjects at risk, and boost the development of new therapies and preventive interventions. The aim is to improve the management and quality of life of neurological patients, and reduce the socio-economic costs of these highly disabling diseases.
- scientific and administrative coordination
- evaluation of neurological drugs for the Italian Medicines Agency (AIFA)
- social neuroscience - improve and inform on behavioral theories and social processes
- biostatistics - develop and implement statistical methodologies for epidemiological, experimental and clinical studies of neurological diseases
Operating unit Clinic, diagnostics and therapy of degenerative diseases of the central nervous system
Director: Dr. Anna Ladogana
phone: (+39) 06 4990 3632
This unit carries out research on degenerative diseases of the central nervous system of relevance for public health, such as Alzheimer's disease, Parkinson's disease, frontotemporal dementias, amyotrophic lateral sclerosis and prion diseases.
The unit maintains the National Registry of Creutzfeldt-Jakob disease (CJD) and related syndromes (link to the Italian website) for the surveillance of CJD over the national territory and coordinates the Transmissible Spongiform Encephalopathies Working Group (GESTISS) for the evaluation of Authorization and International Commerce (AIC) and international dossiers related to prion risk. The CJD registry is included in the European network of the European Center for Disease Prevention and Control (ECDC).
Operating unit Demyelinating and inflammatory diseases of the nervous system
Director: Dr. Francesca Aloisi
phone: (+39) 06 4990 2087
This unit carries out biomedical and translational research on diseases of the nervous system characterized by myelin damage, such as multiple sclerosis and leukodystrophies, in particular megalencephalic leukoencephalopathy with subcortical cysts. The ongoing projects focus on disease causes and mechanisms, identification of disease biomarkers and novel therapeutic targets, and development of remyelinating therapies.